170632-49-2

Upstream product

• 170632-20-9 5-[(benzyl-hydrazono)-(4-methoxy-phenyl)-methyl]-furan-2-carboxylic acid methyl ester 
• 871507-55-0 5-[acetoxy-benzylazo-(4-methoxy-phenyl)-methyl]-furan-2-carboxylic acid methyl ester 
• 100-07-2 4-methoxy-benzoyl chloride 
• 65650-04-6 5-(4-methoxy-benzoyl)-furan-2-carboxylic acid methyl ester 
• 611-13-2 2-furoic acid methyl ester 
• 170632-31-2 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-methoxyindazole 

Relevant academic research and scientific papers

Novel fused pyrazolyl compound

A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective a

Treatment of disorder related to low cyclic GMP levels

Methods of treating a disorder associated with low cGMP levels. The methods include administering to a subject in need thereof an effective amount of a compound having a pyrazolyl core, a first aryl group bonded to 3-C of the pyrazolyl core, and a second

Method of treating disorders related to protease-activated receptors-induced cell activation

A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

1-Benzyl-3-(5′-hydroxymethyl-2′-furyl)-indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis

Antiapoptotic agents based on 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (22, YC-1) derivatives were explored for effective treatment of sepsis and septic shock. We found that compound 22, 1-benzyl-3-(5′-methoxymethyl-2′-furyl)indazole (27), and 1-phe

Synthesis of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole analogues as novel antiplatelet agents

1-Benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (28, YC-1) was selected as the lead compound for systemic structural modification. After screening for antiplatelet activity, SARs of YC-1 analogues were established. Among these potent active derivatives, co